Clinical Effect of Risperidone Combined with Buspirone in the Treatment of Schizophrenia
Objective:To explore the clinical effect of Risperidone combined with Buspirone in the treatment of schizophrenia(SCH).Method:A total of 60 patients with SCH who admitted to Psychiatric Hospital of Qiandongnan Miao and Dong Autonomous Prefecture from January 2022 to February 2023 were selected as the research objects,the patients were divided into the control group and the observation group according to the random number table method,with 30 cases in each group.The control group was given Risperidone,while the observation group was given Buspirone on the basis of the control group,two groups were treated for 2 months.The clinical efficacy,positive and negative symptom scale(PANSS)score,cognitive function,serological indicators,quality of life and adverse reactions were compared between two groups.Result:The total effective rate of the observation group was higher than that of the control group,after treatment,the PANSS scores,central nervous specific protein(S100β)and tumor necrosis factor-α(TNF-α)were lower than those of the control group,the mini-mental state examination(MMSE)score,brain-derived neurotrophic factor(BDNF)and quality of life score were higher than those of the control group,and the differences were statistically significant(P＜0.05);there was no significant difference in the incidence of adverse reactions between two groups(P＞0.05).Conclusion:Risperidone combined with Buspirone can improve the therapeutic effect of SCH,accelerate the disappearance of disease symptoms,reduce cognitive impairment,improve the quality of life of patients,and is safe and reliable.
国家科技期刊平台
NSTL
万方数据
